Atara Biotherapeutics (ATRA) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed Atara Biotherapeutics (ATRA) over the past year, gaining 268.7% versus a loss of 41.8%. Over five years, RLYB leads with a -86.3% price change compared with -97.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($92.6 million vs $90.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | RLYB |
|---|---|---|
| Share price | $9.23 | $16.99 |
| Market cap | $92.65M | $90.26M |
| 1-day change | -1.49% | +0.35% |
| YTD return | -48.98% | +209.58% |
| 1-year return | -41.77% | +268.71% |
| 5-year return | -97.56% | -86.32% |
| P/E ratio (TTM) | — | 2.12 |
| Forward P/E | 5.97 | — |
| EPS (TTM) | $-1.30 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $17.57 |
| 52-week low | $3.92 | $3.67 |
| Distance from 52-week high | -51.79% | -3.32% |
| Analyst consensus | buy | — |
| Avg. price target upside | +48.10% | — |
| Average volume | 53.79K | 21.33K |
| Shares outstanding | 10.04M | 5.31M |
| Employees | 10 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed ATRA by 310.5 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Healthcare · Biotechnology · 10 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Healthcare · Biotechnology · 7 employees
ATRA vs RLYB FAQ
Which is bigger, Atara Biotherapeutics or Rallybio?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $92.65M compared with $90.26M for Rallybio (RLYB).
Which stock has performed better over the past year, ATRA or RLYB?
RLYB returned +268.71% over the past 12 months, compared with -41.77% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.